Compare Edison International Common Stock (EIX) vs Organon & Co. Common Stock (OGN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Edison International Common Stock vs Organon & Co. Common Stock — how do they compare? Edison International Common Stock trades at $55.7 (market cap $21.35B), while Organon & Co. Common Stock trades at $13.58 (market cap $3.62B). The key difference: Edison International Common Stock is far larger — about 5.9× Organon & Co. Common Stock's market cap, and Edison International Common Stock pays the higher dividend (6.33%). Which is the better fit depends on your goals — on Pluang, investors hold Edison International Common Stock for 4 Days and Organon & Co. Common Stock for 0 Days on average.
| EIX | OGN | |
|---|---|---|
Market Cap | $21.35B | $3.62B |
Volume | 15,485,731 | 2,892,999 |
Sector | Utilities | Health |
52-Week High | $80.38 | $13.81 |
52-Week Low | $51.47 | $5.70 |
Typical Hold Time | 4 Days | 0 Days |
Enterprise Value | $64.73B | $11.04B |
Dividend Yield | 6.33% | 0.58% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Edison International (EIX) trades at $55.48, down 0.29% on the day, with a bullish technical signal despite mixed oscillators. The stock offers a high dividend yield of 6.4% and trades below the consensus price target of $59.29. Recent earnings have consistently beaten estimates, with Q3 2026 results pending. However, the stock faces headwinds from unresolved California wildfire liability risks, contributing to a 23% decline in late August 2026.
EIX presents a value opportunity with low P/E (5.73) and P/B (1.22) ratios, strong profitability (ROE 23.06%), and a stable dividend. Key risks include regulatory uncertainty around wildfire costs and a projected decline in 2026 net margin. Analyst sentiment is mixed but leans positive, with 40.5% buy ratings. The stock's upside depends on regulatory clarity and sustained earnings growth.
Organon (OGN) trades at $13.77, showing no change in the latest session. The stock demonstrates strong profitability with 52.68% gross margins and 24.04% ROE, though recent quarterly earnings have missed expectations. Valuation appears reasonable with P/E of 17.65 and P/S of 0.59. The company shows positive cash flow trends with 2026 projections indicating $533M net cash flow. Recent FDA developments for MIUDELLA and VTAMA products highlight ongoing pipeline progress.
OGN presents a mixed outlook with solid fundamentals offset by earnings misses. The healthcare company's improving cash flow and product pipeline offer potential upside, but investor sentiment remains divided with analysts showing cautious optimism. Key risks include execution challenges and competitive pressures in the pharmaceutical sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Edison International Common Stock
Edison International is the parent company of Southern California Edison, an electric utility that supplies and delivers electricity across Southern California. It also owns Trio, an energy advisory business.
Read more on EIX →About Organon & Co. Common Stock
Organon & Co. is a global healthcare company focused on women's health, biosimilars, and established brands, spun off from Merck & Co. in 2021. Its portfolio of more than 70 medicines includes contraception and fertility therapies, immunology and oncology biosimilars, and treatments in cardiovascular, respiratory, and dermatology, distributed in over 140 countries.
Read more on OGN →
